SANUWAVE Health, Inc. filings document a Nevada medical-device company focused on directed-energy systems for advanced wound care and regenerative medicine. Form 8-K reports record results of operations, preliminary financial information, investor presentation materials and material-event disclosures related to the company’s wound care business.
Regulatory filings also cover governance and capital-market disclosure subjects, including annual meeting proxy proposals, director elections, auditor ratification, stockholder advisory votes on executive compensation, officer appointments, compensatory arrangements and separation agreements. Additional filings document accounting matters such as non-reliance on previously issued financial statements connected to historical sales and use tax liabilities.
Form 4 filing overview – SANUWAVE Health, Inc. (SNWV)
Director Gregory M. Bazar reported one insider transaction dated 30 June 2025. The filing shows an award of 1,574 stock options (right to buy common stock) with an exercise price of $32.86 and an expiration date of 30 June 2030. The options were fully vested at the grant date, and Bazar now beneficially owns 1,574 derivative securities directly. No open-market purchases or sales of common shares were disclosed, and there were no changes to non-derivative share holdings.
The transaction appears to be routine director compensation and represents a limited potential dilution given the company’s outstanding share count. No other financial or operational information was provided in this filing.